Overview

Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)

Status:
Active, not recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

This is a 3-part safety study of Vigil, Atezolizumab and their combination in patients who have tumor harvested at surgery and successful manufacturing of Vigil but are ineligible for CL-PTL-119 (the VITAL study) or previously randomized to placebo, and also in patients who have recurrent ovarian cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Gradalis, Inc.

Collaborator:

Roche-Genentech

Treatments:

Antibodies, Monoclonal
Armodafinil
Atezolizumab
Modafinil